文献速递白血病MDS 与骨髓增殖性肿瘤

基因突变对继发于骨髓增殖性肿瘤的急性髓系白血病的治疗反应和预后的影响

Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
PubMed 文献 · Am J Hematol · 2017-12-06

该研究分析了73例由骨髓增殖性肿瘤(MPN)进展为继发性急性髓系白血病(sAML)患者的临床与突变特征,其中24例进行了MPN期与sAML期的比较性二代测序。sAML后中位无事件生存期(EFS)为2.9个月,总生存期(OS)为4.7个月;TP53、TET2和SRSF2突变是独立的阴性预后因素,而常规临床因素未能预测结局。

要点

  • sAML后中位EFS为2.9个月,中位OS为4.7个月。
  • TP53(P=.0001)、TET2(P=.011)和SRSF2(P=.018)为独立预后因素。
  • SRSF2突变者转化时间51.2个月,短于未突变者133.8个月(P<.001)。

核心结论

  • 在sAML阶段,仅突变状态(TP53、TET2、SRSF2)与预后相关,常规临床因素未能预测患者结局。

研究设计与样本

  • 回顾性分析73例由MPN进展为sAML的患者,依据流行病学特征、既往MPN、所接受治疗、ELN预后分组、治疗反应及NGS确定的突变状态评估EFS和OS。
  • 对24例患者进行了MPN期与sAML期的比较性NGS分析。

主要发现

  • sAML后中位EFS为2.9个月(范围:0-48.1),中位OS为4.7个月(范围:0.1-58.8)。
  • 既往MPN类型、ELN2017预后分类、一线治疗或治疗反应之间,EFS或OS均无差异。
  • 单因素分析显示TP53、SRSF2和TET2突变对sAML预后有不良影响。
  • 多因素分析显示TP53(P=.0001)、TET2(P=.011)和SRSF2(P=.018)仍为独立预后因素。
  • SRSF2突变患者转化至sAML的时间为51.2个月(范围:14.7-98),短于SRSF2未突变患者的133.8个月(范围:12.6-411.2)(P<.001)。

关键数值与推荐

  • TP53突变多因素分析P=.0001,TET2突变P=.011,SRSF2突变P=.018。
  • SRSF2突变者转化时间51.2个月(范围:14.7-98) vs SRSF2未突变者133.8个月(范围:12.6-411.2),P<.001。
  • sAML后中位EFS 2.9个月(范围:0-48.1),中位OS 4.7个月(范围:0.1-58.8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemias secondary (sAML) to myeloproliferative neoplasms (MPN) have variable clinical courses and outcomes, but remain almost always fatal. Large cohorts of sAML to MPN are difficult to obtain and there is very little scientific literature or prospective trials for determining robust prognostic markers and efficient treatments. We analyzed event-free survival (EFS) and overall survival (OS) of 73 patients with MPN who progressed to sAML, based on their epidemiological characteristics, the preexisting MPN, the different treatments received, the different prognostic groups and the responses achieved according to the ELN, and their mutational status determined by next-generation DNA sequencing (NGS). For 24 patients, we were able to do a comparative NGS analysis at both MPN and sAML phase. After acute transformation EFS and OS were respectively of 2.9 months (range: 0-48.1) and 4.7 months (range: 0.1-58.8). No difference in EFS or OS regarding the previous MPN, the ELN2017 prognostic classification, the first-line therapy or the response was found. After univariate analysis, three genes, TP53, SRSF2 and TET2, impacted pejoratively sAML prognosis at sAML time. In multivariate analysis, TP53 (P = .0001), TET2 (P = .011) and SRSF2 (P = .018) remained independent prognostic factors. Time to sAML transformation was shorter in SRSF2-mutated patients (51.2 months, range: 14.7-98) than in SRSF2-unmutated patients (133.8 months, range: 12.6-411.2) (P < .001). Conventional clinical factors (age, karyotype, ELN2017 prognostic classification, treatments received, treatments response, Allo-SCT…) failed to predict the patients' outcome. Only the mutational status appeared relevant to predict patients' prognosis at sAML phase.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Venton G, Courtier F, Charbonnier A, et al. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. Am J Hematol. 2017. PMID: 29148089. doi:10.1002/ajh.24973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。